BioNTech Chief Executive Officer Ugur Sahin told Reuters Wednesday that doses of the coronavirus vaccine could be available for some in the U.S. and Europe by next month, pending regulatory approval.
Pfizer and BioNTech said Wednesday that final trial results of their vaccine showed it had a 95% success rate and no serious side effects.
